GlassScriptPhysician profile
Jules C Beal
NPI 1811136187
$8,176.17
in general payments reported to CMS, 2019-2025
8 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $4,935 · 2021: $2,767 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $4,068.28 | 2020-2021 | |
| Livanova USA, INC. | $3,555.11 | 2019-2020 | |
| Sk Life Science, INC. | $194.82 | 2021-2025 | |
| Greenwich Biosciences, INC. | $148.48 | 2019 | |
| Ucb, INC. | $135.71 | 2025 | |
| Biomarin Pharmaceutical INC. | $33.69 | 2020 | |
| Eisai INC. | $26.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jules Beal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.